labetalol has been researched along with Critical Illness in 4 studies
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.
Critical Illness: A disease or state in which death is possible or imminent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our study suggests that nicardipine is a more effective antihypertensive agent than labetalol in an unselected group of patients who develop hypertension in the intensive care unit setting." | 9.16 | Intravenous labetalol compared with intravenous nicardipine in the management of hypertension in critically ill patients. ( Hilleman, DE; Malesker, MA, 2012) |
| " Nicardipine and labetalol are commonly administered for the treatment of acute hypertension following stroke." | 7.91 | Nicardipine Associated Risk of Short-Term Mortality in Critically Ill Patients with Ischemic Stroke. ( Desai, A; Hanni, C; Mohamed, W; Parker, D; Saber, H; Sadeghi, M; Singh, A, 2019) |
| "Our study suggests that nicardipine is a more effective antihypertensive agent than labetalol in an unselected group of patients who develop hypertension in the intensive care unit setting." | 5.16 | Intravenous labetalol compared with intravenous nicardipine in the management of hypertension in critically ill patients. ( Hilleman, DE; Malesker, MA, 2012) |
| " Nicardipine and labetalol are commonly administered for the treatment of acute hypertension following stroke." | 3.91 | Nicardipine Associated Risk of Short-Term Mortality in Critically Ill Patients with Ischemic Stroke. ( Desai, A; Hanni, C; Mohamed, W; Parker, D; Saber, H; Sadeghi, M; Singh, A, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sadeghi, M | 1 |
| Saber, H | 1 |
| Singh, A | 1 |
| Hanni, C | 1 |
| Parker, D | 1 |
| Desai, A | 1 |
| Mohamed, W | 1 |
| Marik, PE | 1 |
| Rivera, R | 1 |
| Malesker, MA | 1 |
| Hilleman, DE | 1 |
| Patel, RV | 1 |
| Kertland, HR | 1 |
| Jahns, BE | 1 |
| Zarowitz, BJ | 1 |
| Mlynarek, ME | 1 |
| Fagan, SC | 1 |
1 review available for labetalol and Critical Illness
| Article | Year |
|---|---|
Hypertensive emergencies: an update.
Topics: Acute Disease; Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; Critical Care; | 2011 |
2 trials available for labetalol and Critical Illness
| Article | Year |
|---|---|
Intravenous labetalol compared with intravenous nicardipine in the management of hypertension in critically ill patients.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Critical Illness; Female; Hospital Charges; Humans; H | 2012 |
Labetalol: response and safety in critically ill hemorrhagic stroke patients.
Topics: Adult; Aged; Blood Pressure; Cerebral Hemorrhage; Cerebrovascular Disorders; Critical Illness; Femal | 1993 |
1 other study available for labetalol and Critical Illness
| Article | Year |
|---|---|
Nicardipine Associated Risk of Short-Term Mortality in Critically Ill Patients with Ischemic Stroke.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Brain Ischemia; Critical Illness; Databases, Factual; | 2019 |